RAPID ACCESS TO INTERVENTION DEVELOPMENT - ADDENDUM

Release Date:  June 16, 1999

P.T.

National Cancer Institute

In the May 11,1998 issue of the NIH Guide for Grants and Contracts, the
National Cancer Institute (NCI) announced a new initiative: Rapid Access to
Intervention Development (RAID).  The purpose of this Notice is to announce
two changes to the RAID program, effective immediately: 1) requests to produce
materials ready for use in clinical trials must have a letter of commitment to
actually conduct the trial from an Institution where the clinical trial would
occur; and, 2) if the receipt dates, February 1 and August 1 of each year,
fall on a weekend or holiday, the receipt date will be the following business
day.  A previous addendum in the December 18,1998 issue of the NIH Guide for
Grants and Contracts clarified that 1) academic investigators now may have
collaborations with small business partners and still qualify for RAID
funding; and, 2) a maximum of two distinct requests for support per
investigator can be submitted per receipt date.  The following is a brief
overview of the RAID program, with a link to the RAID web site.

RAID will make available to academic investigators the preclinical development
contract resources of NCI's Developmental Therapeutics Program.  The goal of
RAID is the rapid movement of novel molecules and concepts from the laboratory
to the clinic for proof-of-principle clinical trials.  RAID will assist
investigators who submit successful requests by providing any (or all) of the
pre-clinical developmental requirements for clinical translation.  These
include, for example, production, bulk supply, good manufacturing practices
(GMP) standards,  formulation, and toxicology.  Suitable types of agents for
RAID include small molecules, biologics, or vaccines.  For more information,
visit the web site, http://dtp.nci.nih.gov/.

Requests for RAID resources are to be submitted as described in the web site. 
Written requests will be evaluated by a specially constituted RAID panel
consisting of selected NCI staff (non voting) and outside experts from
academia and industry.  All requests for support must be submitted directly to
the office listed below under INQUIRIES.

INQUIRIES

Inquiries are encouraged, and the opportunity to clarify issues or questions
is welcome.  Inquiries may be directed to:

RAID, Office of Associate Director
Developmental Therapeutics Program
National Cancer Institute
6130 Executive Boulevard, Suite 843
Bethesda, MD 20892
Rockville, MD 20852 (for express/courier service)
Telephone: (301) 496-8720
FAX: (301) 402-0831
Email: sausville@dtpax2.ncifcrf.gov

Return to Volume Index

Return to NIH Guide Main Index

	Office of Extramural Research (OER)			National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892			Department of Health and Human Services (HHS)
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.